English

TRANSKARYOTIC THERAPIES INC

EDGAR

Quarterly report (10-Q) · filed 2005-05-10

39 filing records in this dataset, filed from 1996-11-26 to 2005-05-10. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

22.6 million USD

2005-03-31 · USD

Exact inputs and evidence

Revenue: 22574000 USD Source

Operating cash flow

-25.2 million USD

2005-03-31 · USD

Exact inputs and evidence

Operating Cash Flow: -25235000 USD Source

Free cash flow

-26.6 million USD

2005-03-31 · USD

Exact inputs and evidence

Operating Cash Flow: -25235000 USD Source
Capital Expenditure: 1362000 USD Source

Cash and cash equivalents: 57.7 million USD 2005-03-31 Source
Exact value

57741000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

83.3 million USD

2004-04-01 – 2005-03-31

Exact inputs and evidence

Revenue: 18167000 USD · 2004-04-01 – 2004-06-30 Source
Revenue: 19558000 USD · 2004-07-01 – 2004-09-30 Source
Revenue: 78126000 USD · 2004-01-01 – 2004-12-31 Source
Revenue: 55159000 USD · 2004-01-01 – 2004-09-30 Source
Revenue: 22574000 USD · 2005-01-01 – 2005-03-31 Source

Net income

-73.4 million USD

2004-04-01 – 2005-03-31

Exact inputs and evidence

Net income: -20210000 USD · 2004-04-01 – 2004-06-30 Source
Net income: -18810000 USD · 2004-07-01 – 2004-09-30 Source
Net income: -65874000 USD · 2004-01-01 – 2004-12-31 Source
Net income: -53171000 USD · 2004-01-01 – 2004-09-30 Source
Net income: -21683000 USD · 2005-01-01 – 2005-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2005-05-10.

Financial data available through: 2004-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2004-12-31
Operating income: 9 of 11 periods available· newest 2002-12-31
Net income: 11 of 11 periods available· newest 2004-12-31
Operating cash flow: 11 of 11 periods available· newest 2004-12-31
Capital expenditure: 11 of 11 periods available· newest 2004-12-31
Total assets: 5 of 11 periods available· newest 2004-12-31
liabilities: No compatible figures in this window
Current assets: 5 of 11 periods available· newest 2004-12-31
Current liabilities: 5 of 11 periods available· newest 2004-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2004-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+32.7%

Prior period

USD 58.89 million

2003-01-01 – 2003-12-31
Current period

USD 78.13 million

2004-01-01 – 2004-12-31

Exact inputs and evidence

78126000 − 58889000 = 19237000 USD

58889000 USD · 2003-01-01 – 2003-12-31
Inspect prior input Prior source
78126000 USD · 2004-01-01 – 2004-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Year-over-year change in Revenue: 19237000 USD Concept: fundies:Revenue Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 78126000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#13415 Input fundies:Revenue: 58889000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#13415
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 9.36 million

Prior period

−USD 75.23 million

2003-01-01 – 2003-12-31
Current period

−USD 65.87 million

2004-01-01 – 2004-12-31

Exact inputs and evidence

-65874000 − -75234000 = 9360000 USD

-75234000 USD · 2003-01-01 – 2003-12-31
Inspect prior input Prior source
-65874000 USD · 2004-01-01 – 2004-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Year-over-year change in Net income: 9360000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -65874000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#15782 Input fundies:NetIncome: -75234000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#15782
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 25.14 million

Prior period

−USD 66.83 million

2003-01-01 – 2003-12-31
Current period

−USD 41.69 million

2004-01-01 – 2004-12-31

Exact inputs and evidence

-41688000 − -66826000 = 25138000 USD

-66826000 USD · 2003-01-01 – 2003-12-31
Inspect prior input Prior source
-41688000 USD · 2004-01-01 – 2004-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Year-over-year change in Operating cash flow: 25138000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -41688000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 Input fundies:OperatingCashFlow: -66826000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-10.5%

Prior period

USD 14.77 million

2003-01-01 – 2003-12-31
Current period

USD 13.23 million

2004-01-01 – 2004-12-31

Exact inputs and evidence

13226000 − 14774000 = -1548000 USD

14774000 USD · 2003-01-01 – 2003-12-31
Inspect prior input Prior source
13226000 USD · 2004-01-01 – 2004-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Year-over-year change in Capital expenditure: -1548000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 13226000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 Input fundies:CapitalExpenditure: 14774000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2004 2004-01-01 – 2004-12-31

Revenue USD 78.13 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 65.87 million −84% of revenue

Cash

Operating cash flow −USD 41.69 million −53% of revenue
Capital expenditure USD 13.23 million 17% of revenue
Free cash flow Derived −USD 54.91 million −70% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2000 Operating loss: operating costs were 996% of revenue.
2001 Operating loss: operating costs were 1,469% of revenue.
2002 Operating loss: operating costs were 476% of revenue.
2003 Not shown: operating income or net income is not reported.
2004 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2000 2000-01-01 – 2000-12-31	7247000	72195000 Derived	-64948000	-13927000 Derived	-51021000	-46702000 Derived	Source 2000-01-01 – 2000-12-31: 7247000 USD Inspect Revenue Open source 2000-01-01 – 2000-12-31: -64948000 USD Inspect Operating Income Open source 2000-01-01 – 2000-12-31: -51021000 USD Inspect Net Income Open source 2000-01-01 – 2000-12-31: -41078000 USD Inspect Operating Cash Flow Open source 2000-01-01 – 2000-12-31: 5624000 USD Inspect Capital Expenditure Open source
2001 2001-01-01 – 2001-12-31	6188000	90929000 Derived	-84741000	-14498000 Derived	-70243000	-94059000 Derived	Source 2001-01-01 – 2001-12-31: 6188000 USD Inspect Revenue Open source 2001-01-01 – 2001-12-31: -84741000 USD Inspect Operating Income Open source 2001-01-01 – 2001-12-31: -70243000 USD Inspect Net Income Open source 2001-01-01 – 2001-12-31: -70183000 USD Inspect Operating Cash Flow Open source 2001-01-01 – 2001-12-31: 23876000 USD Inspect Capital Expenditure Open source
2002 2002-01-01 – 2002-12-31	36500000	173778000 Derived	-137278000	-7516000 Derived	-129762000	-146710000 Derived	Source 2002-01-01 – 2002-12-31: 36500000 USD Inspect Revenue Open source 2002-01-01 – 2002-12-31: -137278000 USD Inspect Operating Income Open source 2002-01-01 – 2002-12-31: -129762000 USD Inspect Net Income Open source 2002-01-01 – 2002-12-31: -104921000 USD Inspect Operating Cash Flow Open source 2002-01-01 – 2002-12-31: 41789000 USD Inspect Capital Expenditure Open source
2003 2003-01-01 – 2003-12-31	58889000	Unavailable	Unavailable	Unavailable	-75234000	-81600000 Derived	Source 2003-01-01 – 2003-12-31: 58889000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: -75234000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: -66826000 USD Inspect Operating Cash Flow Open source 2003-01-01 – 2003-12-31: 14774000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	78126000	Unavailable	Unavailable	Unavailable	-65874000	-54914000 Derived	Source 2004-01-01 – 2004-12-31: 78126000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: -65874000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: -41688000 USD Inspect Operating Cash Flow Open source 2004-01-01 – 2004-12-31: 13226000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 78.1M 2004

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Revenue	7247000	Revenue: 7247000 Open source
20012001-12-31	Revenue	6188000	Revenue: 6188000 Open source
20022002-12-31	Revenue	36500000	Revenue: 36500000 Open source
20032003-12-31	Revenue	58889000	Revenue: 58889000 Open source
20042004-12-31	Revenue	78126000	Revenue: 78126000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

32.7% 2004

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Year over year	No prior comparable period	Revenue: 7247000 Open source
20012001-12-31	Year over year	-14.6%	Revenue: 6188000 Open source Revenue: 7247000 Open source
20022002-12-31	Year over year	489.9%	Revenue: 36500000 Open source Revenue: 6188000 Open source
20032003-12-31	Year over year	61.3%	Revenue: 58889000 Open source Revenue: 36500000 Open source
20042004-12-31	Year over year	32.7%	Revenue: 78126000 Open source Revenue: 58889000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -376.1% 2002

Net margin -84.3% 2004

Free cash flow margin -70.3% 2004

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Operating margin	-896.2%	Operating Income: -64948000 Open source Revenue: 7247000 Open source
20012001-12-31	Operating margin	-1,369.4%	Operating Income: -84741000 Open source Revenue: 6188000 Open source
20022002-12-31	Operating margin	-376.1%	Operating Income: -137278000 Open source Revenue: 36500000 Open source
2003-12-31	Operating margin	Not reported	Revenue: 58889000 Open source
2004-12-31	Operating margin	Not reported	Revenue: 78126000 Open source
20002000-12-31	Net margin	-704%	Net Income: -51021000 Open source Revenue: 7247000 Open source
20012001-12-31	Net margin	-1,135.1%	Net Income: -70243000 Open source Revenue: 6188000 Open source
20022002-12-31	Net margin	-355.5%	Net Income: -129762000 Open source Revenue: 36500000 Open source
20032003-12-31	Net margin	-127.8%	Net Income: -75234000 Open source Revenue: 58889000 Open source
20042004-12-31	Net margin	-84.3%	Net Income: -65874000 Open source Revenue: 78126000 Open source
20002000-12-31	Free cash flow margin	-644.4%	Revenue: 7247000 Open source Operating Cash Flow: -41078000 Open source Capital Expenditure: 5624000 Open source
20012001-12-31	Free cash flow margin	-1,520%	Revenue: 6188000 Open source Operating Cash Flow: -70183000 Open source Capital Expenditure: 23876000 Open source
20022002-12-31	Free cash flow margin	-401.9%	Revenue: 36500000 Open source Operating Cash Flow: -104921000 Open source Capital Expenditure: 41789000 Open source
20032003-12-31	Free cash flow margin	-138.6%	Revenue: 58889000 Open source Operating Cash Flow: -66826000 Open source Capital Expenditure: 14774000 Open source
20042004-12-31	Free cash flow margin	-70.3%	Revenue: 78126000 Open source Operating Cash Flow: -41688000 Open source Capital Expenditure: 13226000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -41.7M 2004

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Operating cash flow	-41078000	Operating Cash Flow: -41078000 Open source
20012001-12-31	Operating cash flow	-70183000	Operating Cash Flow: -70183000 Open source
20022002-12-31	Operating cash flow	-104921000	Operating Cash Flow: -104921000 Open source
20032003-12-31	Operating cash flow	-66826000	Operating Cash Flow: -66826000 Open source
20042004-12-31	Operating cash flow	-41688000	Operating Cash Flow: -41688000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -54.9M 2004

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Free cash flow	-46702000	Operating Cash Flow: -41078000 Open source Capital Expenditure: 5624000 Open source
20012001-12-31	Free cash flow	-94059000	Operating Cash Flow: -70183000 Open source Capital Expenditure: 23876000 Open source
20022002-12-31	Free cash flow	-146710000	Operating Cash Flow: -104921000 Open source Capital Expenditure: 41789000 Open source
20032003-12-31	Free cash flow	-81600000	Operating Cash Flow: -66826000 Open source Capital Expenditure: 14774000 Open source
20042004-12-31	Free cash flow	-54914000	Operating Cash Flow: -41688000 Open source Capital Expenditure: 13226000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2000-12-31	Liabilities / assets	Not reported	Total Assets: 272393000 Open source
2001-12-31	Liabilities / assets	Not reported	Total Assets: 457707000 Open source
2002-12-31	Liabilities / assets	Not reported	Total Assets: 359806000 Open source
2003-12-31	Liabilities / assets	Not reported	Total Assets: 289169000 Open source
2004-12-31	Liabilities / assets	Not reported	Total Assets: 333350000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.62× 2004

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Current assets / current liabilities	16.45×	Current Assets: 247298000 Open source Current Liabilities: 15036000 Open source
20012001-12-31	Current assets / current liabilities	19.21×	Current Assets: 413895000 Open source Current Liabilities: 21544000 Open source
20022002-12-31	Current assets / current liabilities	8.31×	Current Assets: 298492000 Open source Current Liabilities: 35939000 Open source
20032003-12-31	Current assets / current liabilities	10.65×	Current Assets: 225339000 Open source Current Liabilities: 21149000 Open source
20042004-12-31	Current assets / current liabilities	5.62×	Current Assets: 206489000 Open source Current Liabilities: 36735000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
1995 1995-01-01 – 1995-12-31	USD 2.07 million Exact value Exact value: 2074000 USD 1995-01-01 – 1995-12-31: 2074000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 1995-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: 2074000 USD Concept: fundies:NetIncome Period: 1995-01-01 to 1995-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=1995-12-31&surface=latest&period_type=duration&start=1995-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2074000 USD (1995-01-01 to 1995-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-98-012601.txt#2652 The citation records this snapshot. The page link may show a newer release later.	USD 4.32 million Exact value Exact value: 4321000 USD 1995-01-01 – 1995-12-31: 4321000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 1995-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: 4321000 USD Concept: fundies:OperatingCashFlow Period: 1995-01-01 to 1995-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=1995-12-31&surface=latest&period_type=duration&start=1995-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4321000 USD (1995-01-01 to 1995-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-98-012601.txt#2666 The citation records this snapshot. The page link may show a newer release later.	USD 558,000 Exact value Exact value: 558000 USD 1995-01-01 – 1995-12-31: 558000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 1995-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 558000 USD Concept: fundies:CapitalExpenditure Period: 1995-01-01 to 1995-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=1995-12-31&surface=latest&period_type=duration&start=1995-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 558000 USD (1995-01-01 to 1995-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-98-012601.txt#2672 The citation records this snapshot. The page link may show a newer release later.	USD 3.76 million Calculation and evidence 4321000 − 558000 USD Exact free cash flow: 3763000 USD 1995-01-01 – 1995-12-31: 4321000 USD · Inspect Operating Cash Flow · Source 1995-01-01 – 1995-12-31: 558000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 1995-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: 3763000 USD Concept: free-cash-flow Period: 1995-01-01 to 1995-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4321000 USD (1995-01-01 to 1995-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-98-012601.txt#2666 Input fundies:CapitalExpenditure: 558000 USD (1995-01-01 to 1995-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-98-012601.txt#2672 The citation records this snapshot. The page link may show a newer release later.
1996 1996-01-01 – 1996-12-31	−USD 11.97 million Exact value Exact value: -11972000 USD 1996-01-01 – 1996-12-31: -11972000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 1996-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -11972000 USD Concept: fundies:NetIncome Period: 1996-01-01 to 1996-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=1996-12-31&surface=latest&period_type=duration&start=1996-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11972000 USD (1996-01-01 to 1996-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-99-012664.txt#2875 The citation records this snapshot. The page link may show a newer release later.	−USD 9.92 million Exact value Exact value: -9920000 USD 1996-01-01 – 1996-12-31: -9920000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 1996-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -9920000 USD Concept: fundies:OperatingCashFlow Period: 1996-01-01 to 1996-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=1996-12-31&surface=latest&period_type=duration&start=1996-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9920000 USD (1996-01-01 to 1996-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-99-012664.txt#2887 The citation records this snapshot. The page link may show a newer release later.	USD 779,000 Exact value Exact value: 779000 USD 1996-01-01 – 1996-12-31: 779000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 1996-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 779000 USD Concept: fundies:CapitalExpenditure Period: 1996-01-01 to 1996-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=1996-12-31&surface=latest&period_type=duration&start=1996-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 779000 USD (1996-01-01 to 1996-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-99-012664.txt#2893 The citation records this snapshot. The page link may show a newer release later.	−USD 10.7 million Calculation and evidence -9920000 − 779000 USD Exact free cash flow: -10699000 USD 1996-01-01 – 1996-12-31: -9920000 USD · Inspect Operating Cash Flow · Source 1996-01-01 – 1996-12-31: 779000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 1996-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -10699000 USD Concept: free-cash-flow Period: 1996-01-01 to 1996-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9920000 USD (1996-01-01 to 1996-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-99-012664.txt#2887 Input fundies:CapitalExpenditure: 779000 USD (1996-01-01 to 1996-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-99-012664.txt#2893 The citation records this snapshot. The page link may show a newer release later.
1997 1997-01-01 – 1997-12-31	−USD 12.87 million Exact value Exact value: -12871000 USD 1997-01-01 – 1997-12-31: -12871000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 1997-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -12871000 USD Concept: fundies:NetIncome Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12871000 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-00-013392.txt#3084 The citation records this snapshot. The page link may show a newer release later.	−USD 7.49 million Exact value Exact value: -7488000 USD 1997-01-01 – 1997-12-31: -7488000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 1997-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -7488000 USD Concept: fundies:OperatingCashFlow Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7488000 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-00-013392.txt#3096 The citation records this snapshot. The page link may show a newer release later.	USD 2.94 million Exact value Exact value: 2936000 USD 1997-01-01 – 1997-12-31: 2936000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 1997-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 2936000 USD Concept: fundies:CapitalExpenditure Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=1997-12-31&surface=latest&period_type=duration&start=1997-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2936000 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-00-013392.txt#3102 The citation records this snapshot. The page link may show a newer release later.	−USD 10.42 million Calculation and evidence -7488000 − 2936000 USD Exact free cash flow: -10424000 USD 1997-01-01 – 1997-12-31: -7488000 USD · Inspect Operating Cash Flow · Source 1997-01-01 – 1997-12-31: 2936000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 1997-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -10424000 USD Concept: free-cash-flow Period: 1997-01-01 to 1997-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7488000 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-00-013392.txt#3096 Input fundies:CapitalExpenditure: 2936000 USD (1997-01-01 to 1997-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-00-013392.txt#3102 The citation records this snapshot. The page link may show a newer release later.
1998 1998-01-01 – 1998-12-31	−USD 19.97 million Exact value Exact value: -19965000 USD 1998-01-01 – 1998-12-31: -19965000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 1998-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -19965000 USD Concept: fundies:NetIncome Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19965000 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-01-506357.txt#2645 The citation records this snapshot. The page link may show a newer release later.	−USD 17.46 million Exact value Exact value: -17459000 USD 1998-01-01 – 1998-12-31: -17459000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 1998-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -17459000 USD Concept: fundies:OperatingCashFlow Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17459000 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-01-506357.txt#2657 The citation records this snapshot. The page link may show a newer release later.	USD 2.66 million Exact value Exact value: 2660000 USD 1998-01-01 – 1998-12-31: 2660000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 1998-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 2660000 USD Concept: fundies:CapitalExpenditure Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=1998-12-31&surface=latest&period_type=duration&start=1998-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2660000 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-01-506357.txt#2663 The citation records this snapshot. The page link may show a newer release later.	−USD 20.12 million Calculation and evidence -17459000 − 2660000 USD Exact free cash flow: -20119000 USD 1998-01-01 – 1998-12-31: -17459000 USD · Inspect Operating Cash Flow · Source 1998-01-01 – 1998-12-31: 2660000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 1998-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -20119000 USD Concept: free-cash-flow Period: 1998-01-01 to 1998-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17459000 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-01-506357.txt#2657 Input fundies:CapitalExpenditure: 2660000 USD (1998-01-01 to 1998-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000912057-01-506357.txt#2663 The citation records this snapshot. The page link may show a newer release later.
1999 1999-01-01 – 1999-12-31	−USD 44.46 million Exact value Exact value: -44456000 USD 1999-01-01 – 1999-12-31: -44456000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 1999-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -44456000 USD Concept: fundies:NetIncome Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44456000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001104659-02-001166.txt#19684 The citation records this snapshot. The page link may show a newer release later.	−USD 39.48 million Exact value Exact value: -39478000 USD 1999-01-01 – 1999-12-31: -39478000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 1999-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -39478000 USD Concept: fundies:OperatingCashFlow Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39478000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001104659-02-001166.txt#20296 The citation records this snapshot. The page link may show a newer release later.	USD 17.23 million Exact value Exact value: 17227000 USD 1999-01-01 – 1999-12-31: 17227000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 1999-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 17227000 USD Concept: fundies:CapitalExpenditure Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=1999-12-31&surface=latest&period_type=duration&start=1999-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17227000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001104659-02-001166.txt#20564 The citation records this snapshot. The page link may show a newer release later.	−USD 56.71 million Calculation and evidence -39478000 − 17227000 USD Exact free cash flow: -56705000 USD 1999-01-01 – 1999-12-31: -39478000 USD · Inspect Operating Cash Flow · Source 1999-01-01 – 1999-12-31: 17227000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 1999-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -56705000 USD Concept: free-cash-flow Period: 1999-01-01 to 1999-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39478000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001104659-02-001166.txt#20296 Input fundies:CapitalExpenditure: 17227000 USD (1999-01-01 to 1999-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001104659-02-001166.txt#20564 The citation records this snapshot. The page link may show a newer release later.
2000 2000-01-01 – 2000-12-31	−USD 51.02 million Exact value Exact value: -51021000 USD 2000-01-01 – 2000-12-31: -51021000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 2000-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -51021000 USD Concept: fundies:NetIncome Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51021000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-03-011139.txt#5340 The citation records this snapshot. The page link may show a newer release later.	−USD 41.08 million Exact value Exact value: -41078000 USD 2000-01-01 – 2000-12-31: -41078000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 2000-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -41078000 USD Concept: fundies:OperatingCashFlow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41078000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-03-011139.txt#5529 The citation records this snapshot. The page link may show a newer release later.	USD 5.62 million Exact value Exact value: 5624000 USD 2000-01-01 – 2000-12-31: 5624000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 2000-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 5624000 USD Concept: fundies:CapitalExpenditure Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5624000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-03-011139.txt#5595 The citation records this snapshot. The page link may show a newer release later.	−USD 46.7 million Calculation and evidence -41078000 − 5624000 USD Exact free cash flow: -46702000 USD 2000-01-01 – 2000-12-31: -41078000 USD · Inspect Operating Cash Flow · Source 2000-01-01 – 2000-12-31: 5624000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 2000-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -46702000 USD Concept: free-cash-flow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41078000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-03-011139.txt#5529 Input fundies:CapitalExpenditure: 5624000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0001047469-03-011139.txt#5595 The citation records this snapshot. The page link may show a newer release later.
2001 2001-01-01 – 2001-12-31	−USD 70.24 million Exact value Exact value: -70243000 USD 2001-01-01 – 2001-12-31: -70243000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 2001-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -70243000 USD Concept: fundies:NetIncome Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70243000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-04-001291.txt#14156 The citation records this snapshot. The page link may show a newer release later.	−USD 70.18 million Exact value Exact value: -70183000 USD 2001-01-01 – 2001-12-31: -70183000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 2001-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -70183000 USD Concept: fundies:OperatingCashFlow Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70183000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-04-001291.txt#14529 The citation records this snapshot. The page link may show a newer release later.	USD 23.88 million Exact value Exact value: 23876000 USD 2001-01-01 – 2001-12-31: 23876000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 2001-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 23876000 USD Concept: fundies:CapitalExpenditure Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=2001-12-31&surface=latest&period_type=duration&start=2001-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 23876000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-04-001291.txt#14631 The citation records this snapshot. The page link may show a newer release later.	−USD 94.06 million Calculation and evidence -70183000 − 23876000 USD Exact free cash flow: -94059000 USD 2001-01-01 – 2001-12-31: -70183000 USD · Inspect Operating Cash Flow · Source 2001-01-01 – 2001-12-31: 23876000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 2001-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -94059000 USD Concept: free-cash-flow Period: 2001-01-01 to 2001-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70183000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-04-001291.txt#14529 Input fundies:CapitalExpenditure: 23876000 USD (2001-01-01 to 2001-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-04-001291.txt#14631 The citation records this snapshot. The page link may show a newer release later.
2002 2002-01-01 – 2002-12-31	−USD 129.76 million Exact value Exact value: -129762000 USD 2002-01-01 – 2002-12-31: -129762000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 2002-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -129762000 USD Concept: fundies:NetIncome Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:NetIncome: -129762000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#15782 The citation records this snapshot. The page link may show a newer release later.	−USD 104.92 million Exact value Exact value: -104921000 USD 2002-01-01 – 2002-12-31: -104921000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 2002-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -104921000 USD Concept: fundies:OperatingCashFlow Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -104921000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 The citation records this snapshot. The page link may show a newer release later.	USD 41.79 million Exact value Exact value: 41789000 USD 2002-01-01 – 2002-12-31: 41789000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 2002-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 41789000 USD Concept: fundies:CapitalExpenditure Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=2002-12-31&surface=latest&period_type=duration&start=2002-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 41789000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.	−USD 146.71 million Calculation and evidence -104921000 − 41789000 USD Exact free cash flow: -146710000 USD 2002-01-01 – 2002-12-31: -104921000 USD · Inspect Operating Cash Flow · Source 2002-01-01 – 2002-12-31: 41789000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 2002-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -146710000 USD Concept: free-cash-flow Period: 2002-01-01 to 2002-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -104921000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 Input fundies:CapitalExpenditure: 41789000 USD (2002-01-01 to 2002-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.
2003 2003-01-01 – 2003-12-31	−USD 75.23 million Exact value Exact value: -75234000 USD 2003-01-01 – 2003-12-31: -75234000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 2003-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -75234000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75234000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#15782 The citation records this snapshot. The page link may show a newer release later.	−USD 66.83 million Exact value Exact value: -66826000 USD 2003-01-01 – 2003-12-31: -66826000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 2003-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -66826000 USD Concept: fundies:OperatingCashFlow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66826000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 The citation records this snapshot. The page link may show a newer release later.	USD 14.77 million Exact value Exact value: 14774000 USD 2003-01-01 – 2003-12-31: 14774000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 2003-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 14774000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14774000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.	−USD 81.6 million Calculation and evidence -66826000 − 14774000 USD Exact free cash flow: -81600000 USD 2003-01-01 – 2003-12-31: -66826000 USD · Inspect Operating Cash Flow · Source 2003-01-01 – 2003-12-31: 14774000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 2003-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -81600000 USD Concept: free-cash-flow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66826000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 Input fundies:CapitalExpenditure: 14774000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.
2004 2004-01-01 – 2004-12-31	−USD 65.87 million Exact value Exact value: -65874000 USD 2004-01-01 – 2004-12-31: -65874000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Net Income: -65874000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65874000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#15782 The citation records this snapshot. The page link may show a newer release later.	−USD 41.69 million Exact value Exact value: -41688000 USD 2004-01-01 – 2004-12-31: -41688000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Operating Cash Flow: -41688000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41688000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 The citation records this snapshot. The page link may show a newer release later.	USD 13.23 million Exact value Exact value: 13226000 USD 2004-01-01 – 2004-12-31: 13226000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Capital Expenditure: 13226000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13226000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.	−USD 54.91 million Calculation and evidence -41688000 − 13226000 USD Exact free cash flow: -54914000 USD 2004-01-01 – 2004-12-31: -41688000 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 13226000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TRANSKARYOTIC THERAPIES INC · 2004-12-31 TRANSKARYOTIC THERAPIES INC (edgar:885259) Free cash flow: -54914000 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/885259?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41688000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16135 Input fundies:CapitalExpenditure: 13226000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/885259/0000950135-05-001487.txt#16225 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

39 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000885259, 885259, edgar:885259

TRANSKARYOTIC THERAPIES INC

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2004 2004-01-01 – 2004-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation